Affiliation:
1. Grone Gesundheitsakademie Weimar, Germany
2. Laboratory of Neuroanatomy of the Peptidergic Systems, Institute of Neurosciences
of Castilla y León (INCYL), Grupo GIR USAL: BMD (Bases Moleculares del Desarrollo), University of Salamanca, 37007,
Salamanca, Spain
Abstract
Abstract:
Scintigraphic imaging was satisfactory in animal experiments, i.e., in the radioimmunodetection with
125J anti-tissue polypeptide antigen monoclonal antibodies and implanted HELA cell carcinomas. Unlabeled anti-
mouse antibodies (AMAB), in a surplus of 40:1, 200:1 and 4000:1 compared to the radioactive antibody,
were administered five days after administering the 125I anti-TPA antibody (RAAB). In immunoscintigraphies,
radioactivity accumulated in the liver immediately after administering the secondary antibody, and the tumor's
imaging worsened. It can be expected that imunoscintigraphic imaging might improve when radioimmunodetection
is re-performed after the formation of human anti-mouse antibodies (AMAB) and when the ratio of the primary
to the secondary antibody is nearly equivalent because, in this ratio, the formation of immune complexes
might be accelerated. It is possible to measure the quantity of formed anti-mouse antibodies (AMAB) with immunography
measurements. A second administration of diagnostic or therapeutic monoclonal antibodies might
lead to the formation of immune complexes if the quantities of the monoclonal antibodies and the anti-mouse
antibodies have an equivalent ratio. A second performance of the radioimmunodetection four to eight weeks after
the first radioimmunodetection can achieve better tumor imaging because human anti-mouse antibodies
(AMAB) can be formed. Immune complexes of the radioactive antibody and the human anti-mouse antibody
(AMAB) can be formed to concentrate radioactivity in the tumor.
Publisher
Bentham Science Publishers Ltd.
Subject
Drug Discovery,Pharmacology